Table 2. Safety Profile: Number of participants (%) experiencing any event

	PBO	BIIB059				OVERALL
	N=33	50 mg N=26	150 mg N=25	450 mg N=48	Pooled N=99	N=132
Any Event, n(%)	18 (54.5)	17 (65.4)	12 (48)	33 (68.8)	62 (62.6)	80 (60.6)
Severity						
Mild	11 (33.3)	11 (42.3)	8 (32.0)	19 (39.6)	38 (38.4)	49 (37.1)
Moderate	4 (12.1)	6 (23.1)	3 (12.0)	12 (25.0)	21 (21.2)	25 (18.9)
Severe	3 (9.1)	0	1 (4.0)	2 (4.2)	3 (3.0)	6 (4.5)
Related events	6 (18.2)	9 (34.6)	4 (16.0)	16 (33.3)	29 (29.3)	35 (26.5)
Serious events	2 (6.1)	0	3 (12.0)	2 (4.2)	5 (5.1)	7 (5.3)
Related serious events	1 (3.0)	0	1 (4.0)	1 (2.1)	2 (2.0)	3 (2.3)
Events leading to drug withdrawal	0	1 (3.8)	1 (4.0)	1 (2.1)	3 (3.0)	3 (2.3)
Events leading to study withdrawal	0	0	0	1 (2.1)	1 (1.0)	1 (0.8)
Fatal events	0	0	0	0	0	0

Alliance, Sanford Consortium, Consultant of: Genentech, Nektar, BMS, Janssen, AstraZeneca, Biogen, Vielabio, Equillium, Eli Lilly, ILTOO, Abbvie, Amgen, Roche, Gilead, Ronald van Vollenhoven Grant/research support from: AbbVie, Arthrogen, Bristol-Myers Squibb, GlaxoSmithKline, Lilly, Pfizer, and UCB, Consultant of: AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, GSK, Janssen, Lilly, Medac, Merck, Novartis, Pfizer, Roche, and UCB, Filippa Nyberg Consultant of: Biogen, Benjamin Kaffenberger Grant/research support from: Amgen, Biogen, InflaRx, Veloce Biopharmaceuticals, Dermatology Foundation, Saira Sheikh: None declared, Goran Radunovic: None declared, XIAOBI HUANG Shareholder of: Biogen, Employee of: Biogen, HUA CARROLL Shareholder of: Biogen, Employee of: Biogen, Francois Gaudreault Shareholder of: Biogen, Employee of: Biogen, Adam Meyers Shareholder of: Biogen, Employee of: Biogen, Catherine Barbey Shareholder of: Biogen, Employee of: Biogen, Cristina Musselli Shareholder of: Biogen, Employee of: Biogen, NATHALIE FRANCHIMONT Shareholder of: Biogen, Employee of: Biogen

DOI: 10.1136/annrheumdis-2020-eular.5743

OP0194 **IMMUNOSUPPRESSIVE EFFECT OF TOLEROGENIC DENDRITIC CELLS ON AUTOLOGOUS T-CELLS IN PATIENTS WITH RHEUMATOID ARTHRITIS**

Y. Kurochkina[1], T. Tyrinova[2], O. Leplina[2], M. Tikhonova[2], A. Sizikov[2], O. Chumasova[2], A. Ostanin[2], E. Chernykh[2]. *[1]Research Institute of Clinical and Experimental Lymphology - Branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Science, Novosibirsk, Russian Federation; [2]Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation*

Background: Dendritic cells (DCs) are known to contribute to the pathogenesis of rheumatoid arthritis (RA) through presentation of cartilage glycoprotein, production of proinflammatory cytokines and activation of Th1/Th17 responses. Along with stimulating activity, DCs may exhibit suppressive functions via capacity to induce T cell apoptosis/anergy and to generate regulatory T cells. Since these DCs have potential to control autoreactive T-lymphocytes, the enhancing of tolerogenic properties of DCs seems to be a new important strategy in treatment of RA. However, it remains unclear whether autoreactive T lymphocytes are sensitive to the immunosuppressive effects of DC.
Objectives: The aim of our study is to investigate the mechanisms of the inhibitory effect of dexamethasone-modified DCs (dexDCs) in patients with RA on autologous T cells.
Methods: Twenty patients with RA with high and moderate activity of disease were recruited in this study. All patients fullfield ACR/EULAR criteria (2010). All studies were performed after receiving informed consent. DCs were generated from blood monocytes culturing for 5 days with GM-CSF and IFN-α in the presence dexamethasone, applied on third day. LPS as maturation stimuli was added on fourth day. The study evaluated the ability of dexDCs to induce T cell apoptosis, inhibit the production of Th1 and Th17 cytokines in auto-mixed leukocytes culture (MLC), induce the activation of T-regulatory cells, and inhibit the purified protein derivative (PPD)-specific immune response.
Results: We revealed that dexDCs markedly suppressed the production of IFN-γ and IL-17, while the decreasing of IL-4 and IL-13 was less pronounced. Thus, in comparison with Th2 cells, Th1 and Th17 T lymphocytes were more sensitive to suppressor effects of dexDCs. We also revealed a significant increasing of cells in the stage of late apoptosis (An+Pi+) during the cultivation of autologous T cells with dexDCs. We have also proved the suppressive effect of dexDCs on culture T cells that are co-cultivated with mature DCs (reduction of proliferation from 2700 cpm to 1500 cpm, p=0.0015). In addition, we have shown the ability of dexDCs to induce T-regulatory cells with a phenotype CD4+IL10+Tr1. In conclusion, we have shown the ability of PPD-loaded dexDCs to inhibit the proliferative response of both mature DCS and mature dexDCs-loaded PPD, that indicates the ability of dexDCs to possess antigen-specific suppression.
Conclusion: The data obtained indicate that, dexDCs from RA patients have an immunosuppressive effect on autologous T cells through the induction of apoptosis, anergia and activation of T regulatory cells that authorise their application as a DCs-vaccine.
Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2020-eular.1291

Creating in vitro patients - how to best model disease

OP0195 **VASCULARIZED THREE-DIMENSIONAL MODELS OF HUMAN SKIN FIBROSIS**

A. E. Matei[1], C. W. Chen[1], L. Kiesewetter[2], A. H. Györfi[1], Y. N. LI[1], T. Trinh-Minh[1], T. Van Kuppevelt[3], J. Hansmann[2,4], A. Juengel[5], G. Schett[1], F. Groeber-Becker[2,6], J. Distler[1]. *[1]Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany; [2]Translational Center Würzburg, Fraunhofer Translational Center Regenerative Therapies, Fraunhofer Institute for Silicate Research (ISC), Würzburg, Germany; [3]Radboud Institute for Molecular Life Sciences, Department of Biochemistry, Radboud University Medical Center, Nijmegen, Netherlands; [4]University for Applied Sciences Würzburg-Schweinfurt, Würzburg, Germany; [5]Center of Experimental Rheumatology, University Hospital Zurich/Zurich Center of Integrative Human Physiology (ZIHP), Zürich, Switzerland; [6]Department for Tissue Engineering and Regenerative Medicine, Würzburg University Medical Center, Würzburg, Germany*

Background: The complex pathophysiological processes that result in fibrotic tissue remodeling in systemic sclerosis involve interplay between multiple cell types (1). Experimental models of fibrosis are essential to provide a conceptual understanding of the pathogenesis of these diseases and to test antifibrotic drugs. Current models of fibrosis have important limitations: the *in vivo* models rely on species that are phylogenetically distant, whereas the *in vitro* models are oversimplified cultures of a single cell type in an artificial two-dimensional environment of excessive stiffness, which imposes an unphysiological cell polarization (2).
Objectives: Here we evaluated the potential use of vascularized, three-dimensional *in vitro* human skin equivalents as a novel model of skin fibrosis and a platform for the evaluation of antifibrotic drugs.
Methods: Skin equivalents were generated by seeding human endothelial cells, fibroblasts and keratinocytes on a decellularized porcine extracellular matrix with perfusable vascular structure. The skin models were cultured for one month in a system that ensured perfusion of the vascular network at physiological pressure. Fibrotic transformation induced by TGFβ and response to nintedanib as an established antifibrotic drug was evaluated by capillary Western immunoassays, qPCR, histology and immunostaining.
Results: The vascularized human skin equivalents formed the major skin structures relevant for the pathogenesis of fibrosis: a polarized, fully matured epidermis, a stratified dermis and a perfused vessel system with small capillaries. Exposure to TGFβ led to the fibrotic transformation of the skin equivalents, with activated TGFβ downstream pathways, increased fibroblast-to-myofibroblast transition and excessive deposition of extracellular matrix. Treatment of models exposed to TGFβ with nintedanib (a drug with proven antifibrotic effects) ameliorated the fibrotic transformation of skin equivalents with reduced TGFβ signaling, fibroblast-to-myofibroblast transition and decreased extracellular matrix deposition.